Core Insights - Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton, expanding access to approximately 16 million beneficiaries in the U.S. [1][2] Group 1: Company Developments - Lifeward Ltd. announced that Aetna issued prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, recognizing it as medically necessary for individuals with spinal cord injuries [1][2] - The ReWalk Personal Exoskeleton is an FDA-approved technology that enables individuals with spinal cord injuries to achieve functional ambulation, with multiple peer-reviewed studies supporting its benefits [2][3] Group 2: Market Impact - The recent approvals for prior authorization from three major Medicare Advantage insurers signify a significant advancement in access to exoskeletal rehabilitation technology for patients and providers [3][4] - A nurse with a spinal cord injury expressed that access to the ReWalk device represents a life-changing opportunity, emphasizing the importance of innovative mobility devices for dignity and independence [4] Group 3: Company Mission and Products - Lifeward is committed to driving innovation in medical technology to improve the lives of individuals with physical limitations or disabilities, with a product portfolio that includes the ReWalk Exoskeleton and other rehabilitation solutions [6][7]

Luigi Mangione will face murder and weapons charges in a Manhattan court in June for the killing of UnitedHealthcare CEO Brian Thompson, three months before jury selection in his federal trial for crimes related to the same killing. https://t.co/GNRnJQLW7o ...

Luigi Mangione will not face the death penalty for allegedly fatally shooting UnitedHealthcare CEO Brian Thompson, a federal judge ruled Friday, delivering a major setback to prosecutors. MS NOW Legal Affairs Reporter Fallon Gallagher joins Ana Cabrera with the latest. MS NOW: My Source for News, Opinion, and the World. Same mission. New name. » Subscribe to MS NOW: https://www.youtube.com/@msnow MS NOW is the go-to destination for domestic and international breaking news, and best-in-class opinion journali ...

Federal prosecutors can’t seek the death penalty against Luigi Mangione in the killing of UnitedHealthcare CEO Brian Thompson. Listen to that and the latest stories on Bloomberg News Now. https://t.co/CoThOn2yxa ...

Luigi Mangione will not face the death penalty for allegedly killing UnitedHealthcare CEO Brian Thompson, judge rules.https://t.co/4lLelNlx43 https://t.co/1YW9d09RZf ...

Core Insights - Heartflow, Inc. has received comprehensive coverage for its AI-powered Heartflow Plaque Analysis from Aetna, marking a significant milestone in expanding access to this technology for coronary artery disease [1][3] - Aetna is the fourth major national commercial insurer to provide this coverage, following similar decisions by Humana, Cigna, and UnitedHealthcare, which enhances the accessibility of Heartflow Plaque Analysis across the United States [1][3] - The new Category I CPT payment code 75577 for Heartflow Plaque Analysis, effective January 1, 2026, establishes a reimbursement structure that supports the financial viability of this service [2][4] Coverage and Policy Changes - Aetna's updated policy became effective on December 23, 2025, allowing coverage for patients with acute or stable chest pain and mild-to-moderate coronary artery narrowing [3] - The policy aims to facilitate earlier diagnosis and personalized management of coronary artery disease through AI-driven plaque analysis [3][4] Clinical Validation and Impact - The DECIDE Registry data indicates that over 50% of patients had their medical management altered when Heartflow Plaque Analysis was utilized, demonstrating its clinical impact [5] - Heartflow Plaque Analysis has been validated through over 100 studies involving more than 365,000 patients, showcasing its effectiveness in real-world clinical practice [7][8] Technological Advancements - Heartflow's technology is the only FDA-cleared AI-powered plaque quantification tool, achieving 95% agreement with the gold standard, IVUS [6] - The platform utilizes a proprietary data pipeline built from over 160 million annotated CTA images, enhancing the accuracy and reproducibility of insights [7] Market Presence and Adoption - Heartflow has been adopted by more than 1,400 institutions globally, indicating a strong commercial presence and commitment to expanding access to its innovative solutions [7] - The company aims to redefine cardiovascular care by transforming coronary artery disease management through early detection and personalized treatment strategies [9]

Core Insights - Lifeward Ltd. has received prior authorization from Humana Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access to innovative medical technology for individuals with spinal cord injuries [1][2][3] - Humana and UnitedHealthcare, the two largest Medicare Advantage providers in the U.S., now account for 47% of all Medicare Advantage enrollees eligible for reimbursement for the ReWalk 7 [1][3] Company Developments - The approval from Humana is expected to enhance Lifeward's revenue and cash flow dynamics, providing a clearer foundation for scalable growth in the U.S. market [1][3] - Lifeward has been actively submitting claims for reimbursement under both traditional Medicare and Medicare Advantage Plans since the Centers for Medicare & Medicaid Services (CMS) implemented a formal reimbursement pathway for personal exoskeletons in 2024 [3] Industry Context - The approval of coverage for the ReWalk 7 under Humana's Medicare Advantage Plan reflects a broader trend of increasing acceptance of innovative medical technologies within the healthcare system [2][3] - Nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for the ReWalk 7, indicating a growing recognition of the clinical and functional value of personal exoskeleton technology [3]

Core Insights - Stadium Capital Management has initiated a new position in Insperity, acquiring 263,715 shares valued at approximately $13 million, making it one of the fund's largest holdings [1][2][6] - Insperity's stock has significantly underperformed, down 55% over the past year, while the S&P 500 has increased by 14% during the same period [3][8] Company Overview - Insperity provides human resources outsourcing, payroll administration, employee benefits, compliance, and cloud-based HR management solutions, primarily targeting small and mid-sized businesses in the U.S. [5] - The company reported a trailing twelve months (TTM) revenue of $6.8 billion and a net income of $17 million, with a dividend yield of 7% [4] Financial Performance - In the last quarter, Insperity's revenue rose by 4% to $1.6 billion, but the company faced a net loss of $20 million due to elevated healthcare costs, with adjusted EBITDA falling to $10 million [7][8] - Management has indicated progress on cost controls and the benefits of a new multi-year contract with UnitedHealthcare, which is expected to reduce large-claim cost exposure starting in 2026 [6][8] Investment Perspective - The significant investment by Stadium Capital suggests confidence in Insperity's potential for operational recovery rather than a structural decline, despite current challenges [6][8] - The current stock price reflects pessimism about future conditions, presenting a potential opportunity for investors who believe in the company's long-term recurring-revenue model [8]

As the accused killer of UnitedHealthcare’s CEO heads to court this week, his support has proven surprisingly enduring. https://t.co/WXio6aQVDk ...

Core Insights - Panacea Life Sciences Holdings, Inc. has launched Benivita PLSH, a new venture aimed at transforming access to non-insurance benefits, telemedicine services, and wellness programs across the U.S. [1][2] - The platform combines PLSH's operational infrastructure, Benivita's marketing expertise, and New Benefits, Inc.'s leadership in benefit aggregation to provide affordable access to benefits typically available only to corporate employees [2][3] Company Overview - Benivita PLSH offers a membership-based platform with plans starting at $59.95 per month for individuals, which includes 24/7 virtual urgent care, primary care, mental wellness visits, and discounted prescriptions [3][4] - The venture is supported by New Benefits Inc., which serves over 25 million members and provides exclusive licensing for the partnership [3] Market Opportunity - The U.S. telemedicine market was valued at $81 billion in 2024 and is projected to grow to $395.6 billion by 2034, with a CAGR of approximately 17.3% [5] - Benivita PLSH aims to capture significant market share in this expanding segment by offering a scalable and transparent platform [5] Financial Projections - Financial forecasts indicate EBITDA of $1.2 million in 2026, $5.2 million in 2027, and $8.3 million in 2028, with a target of enrolling 100,000 members within 36 to 60 months [9] - The venture is particularly focused on underserved markets, including the U.S. Latino population, which represents nearly 20% of the nation's population [9] Strategic Partnerships - The partnership integrates technology from By Design Technologies and Shapetech Solutions to enhance customer experience and operational efficiency [8] - PLSH will own 100% of Benivita PLSH and has issued 16 million restricted common shares to Benivita Inc., with performance-based incentives tied to EBITDA [9]